ライフサイエンスコーパス: antibody therapeutic

1 ole of isotype for an influenza A monoclonal antibody therapeutic.

2 of binding mechanisms, and to design future antibody therapeutics.

3 t for design of next-generation vaccines and antibody therapeutics.

4 egy for the rational design of more powerful antibody therapeutics.

5 cturing, helped to launch this modern era of antibody therapeutics.

6 owerful and universal platform for advancing antibody therapeutics.

7 resistance to vaccine-induced antibodies and antibody therapeutics.

8 le, safer, and effective delivery system for antibody therapeutics.

9 ture development of safer and more effective antibody therapeutics.

10 litate development of vaccines and candidate antibody therapeutics.

11 to host cells, and is the intended target of antibody therapeutics.

12 portant for designing safe and selective CNS antibody therapeutics.

13 to the development of recombinant monoclonal antibody therapeutics.

14 ntages inherent to chronic administration of antibody therapeutics.

15 st commonly adopted isotype among monoclonal antibody therapeutics.

16 lls are an emerging class of next-generation antibody therapeutics.

17 information on the higher order structure of antibody therapeutics.

18 in ongoing rational design of EGFR-targeted antibody therapeutics.

19 ze them towards the engineering of candidate antibody therapeutics.

20 olecule inhibitors has lagged behind that of antibody therapeutics.

21 mor-specific antigens that are accessible to antibody therapeutics.

22 the experimental immunogenicity of existing antibody therapeutics.

23 proliferative effects of potential anti-HER3 antibody therapeutics.

24 ties during the discovery and development of antibody therapeutics.

25 uences for efficacy of emerging vaccines and antibody therapeutics.

26 al for assessing the therapeutic efficacy of antibody therapeutics.

27 Many next generation antibody therapeutics achieve enhanced potency but often

28 r supporting the development of vaccines and antibody therapeutics against HCMV.

29 red, offering the potential of intracellular antibody therapeutics against human immunodeficiency vir

30 ries such as rCIG can be utilized to develop antibody therapeutics against present and future SARS-Co

31 ctivity, gene therapies targeting NFATc1 and antibody therapeutics against RANK pathway, effectively

32 for the design of resilient, next-generation antibody therapeutics against SARS-CoV-2 VOCs.

33 Monoclonal antibody therapeutics aimed to neutralize PCSK9 have bee

34 ion procedure applicable to both full-length antibody therapeutics and antibody-antigen complexes.

35 te that our method enables quantification of antibody therapeutics and antigen biomarkers in both cli

36 cape-mutation maps enable rational design of antibody therapeutics and assessment of the antigenic co

37 tigenic targets, compare them to traditional antibody therapeutics and CAR T cells, and review the va

38 ance to public health as options for passive antibody therapeutics and even active prophylactics.

39 odies will accelerate the development of new antibody therapeutics and provide guidance for the ratio

40 MrkA as a promising target for K. pneumoniae antibody therapeutics and vaccines.

41 the development of next generation "reactive antibody" therapeutics and diagnostics.

42 he discovery and development of vaccines and antibody therapeutics, and help us gain a deeper underst

43 of humoral immunity to SARS-CoV-2 infection, antibody therapeutics, and vaccination.

44 ped a highly diverse, recombinant polyclonal antibody therapeutic anti-SARS-CoV-2 immunoglobulin hype

45 Nivolumab, a monoclonal antibody therapeutic approved by the FDA, binds to PD-1

46 Antibody therapeutics are a large and rapidly expanding

47 strategies for improving stability of human antibody therapeutics are discussed.

48 Antibody therapeutics are exciting opportunities to atta

49 Although the positive effects of antibody therapeutics are long-lasting, any acute advers

50 Nearly half of the marketed antibody therapeutics are used in oncology.

51 ble) region is a vital component of existing antibody therapeutics, as well as many next generation b

52 velopment of a novel, host receptor-targeted antibody therapeutic broadly applicable to the treatment

53 The drug discovery process for antibody therapeutic candidates however is time- and cos

54 Antibody therapeutic candidates must exhibit not only ti

55 Furthermore, the monoclonal antibody therapeutics casirivimab and imdevimab had robu

56 decade ago, the realization that monoclonal antibody therapeutics could be engineered to improve the

57 f a large set of post-phase-I clinical-stage antibody therapeutics (CSTs) and calculate in silico met

58 Our findings redefine the influenza-specific antibody therapeutic design and support Fc-optimized, no

59 related to the effectiveness of vaccines and antibody therapeutics developed against the unmutated wi

60 The emerging array of antibody therapeutics developed using transgenic technol

61 eterminants could be targeted for vaccine or antibody therapeutic development against multiple alphav

62 ulate them for small-molecule and monoclonal antibody therapeutics development.

63 Moreover, antibody therapeutics directly inhibit transneuronal spr

64 ad-spectrum vaccine capable of generating an antibody therapeutic effective against the multiple stra

65 nderstanding how viral variants might affect antibody therapeutic efficacy.

66 ay have important implications for improving antibody therapeutic efficacy.

67 tion, thereby informing immunogen design and antibody therapeutic efforts.

68 Both endogenous antibodies and a subset of antibody therapeutics engage Fc gamma receptor (FcgammaR

69 Antibody therapeutics Evusheld and Bebtelovimab remain e

70 luble ligands have commonly been targeted by antibody therapeutics for cancers and other diseases.

71 iding a rationale to test their potential as antibody therapeutics for diverse neurological and other

72 illustrated here by multiple generations of antibody therapeutics for human epidermal growth factor

73 ngs provide insights into engineering potent antibody therapeutics for other disease targets.

74 (SARS-CoV-2) possess mutations that prevent antibody therapeutics from maintaining antiviral binding

75 ering methodology for generating fully human antibody therapeutics from murine mAbs produced from sta

76 roperties will differentiate next generation antibody therapeutics from traditional IgG1 scaffolds.

77 particular challenge to targeting EGFR with antibody therapeutics has been resistance, resulting fro

78 Beyond IgG, antibody therapeutics have blossomed into multiple alter

79 Over the past 25 years, antibody therapeutics have emerged as clinically and com

80 tions such as antibody arrays and monoclonal antibody therapeutics have increased the demand for more

81 he risk of developing de novo donor-specific antibodies, therapeutic immunosuppression is the most ob

82 We provide a snapshot of current antibody therapeutics including their formats, common ta

83 of the many promising future directions with antibody therapeutics, including the application of arti

84 ntary determining region of the FDA approved antibody therapeutic ipilimumab used as a model system.

85 itial criteria for success of any protein or antibody therapeutic is to understand its binding charac

86 Aggregation of monoclonal antibody therapeutics is a serious concern that is belie

87 The future of engineered antibody therapeutics is bright, with the global mAb mar

88 The utility of antibody therapeutics is hampered by potential cross-rea

89 ecies, and the mechanism of these monoclonal antibody therapeutics is still not understood in detail.

90 An alternative to conventional antibody therapeutics is the use of shark new antigen va

91 One of the greatest benefits of antibody therapeutics is their extraordinarily long seru

92 erved in all 48 genomes, deployed monoclonal antibody therapeutics (mAb114 and ZMapp) should be effic

93 Efforts to create vaccines and antibody therapeutics must account for the evolutionary

94 cern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-g

95 Antibody therapeutics now often start with fully human v

96 Antibody therapeutics offer effective treatment options

97 major problem in an industrial setting where antibody therapeutics often require high local concentra

98 the exploration of promising glycoforms for antibody therapeutics.Post-translational modifications c

99 the non-clinical safety profile of TCR-like antibody therapeutics prior to first-in-human clinical a

100 critical quality attribute for a monoclonal antibody therapeutic product due to its perceived signif

101 ver, the design and discovery of early-stage antibody therapeutics remain a time and cost-intensive e

102 s (BA.1, BA.1.1, and BA.2) of two monoclonal antibody therapeutics (S309 [Vir Biotechnology] monother

103 ed glycan profiles on recombinant monoclonal antibody therapeutics significantly affect antibody biol

104 lds offer low-cost alternatives to classical antibody therapeutic strategies and some have shown earl

105 tforms will be applicable to a wide range of antibody therapeutic studies for different species.

106 Systemic advances include antibody therapeutics such as bevacizumab, which targets

107 Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobuli

108 his review will discuss the pros and cons of antibody therapeutics targeted at bacterial infections.

109 o accelerate the development of vaccines and antibody therapeutics targeting a broad range of viruses

110 of acute GVHD and enable evaluation of human antibody therapeutics targeting human T cells.

111 t engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-

112 bloodstream infection; however, vaccines and antibody therapeutics targeting staphylococcal surface m

113 Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SAR

114 marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rend

115 Humanization procedures aim to produce antibody therapeutics that do not elicit an immune respo

116 micron and the need for rapid development of antibody therapeutics that maintain potency against emer

117 the wise use of combination-based monoclonal antibody therapeutics to improve outcomes and prevent re

118 ryptococcal meningitis and for the design of antibody therapeutics to treat other infectious diseases

119 cans including those found on the monoclonal antibody therapeutic trastuzumab.

120 obodies, a fully synthetic affibody, and the antibody therapeutics trastuzumab and cetuximab.

121 n models revealed windows of opportunity for antibody therapeutic treatment that correlated well with

122 The development of new vaccines and antibody therapeutics typically takes several years and

123 We developed a peanut-specific IgG4 antibody therapeutic with convincing preclinical efficac

124 l optionality for developing next-generation antibody therapeutics with broader utility and improved

125 s and the worldwide approval of at least 212 antibody therapeutics with tens of millions of patients